Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

Company Developments - Oncolytics Biotech Inc. announced the presentation of two data sets showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers at the 2025 ASCO Gastrointestinal Cancers Symposium [2][8] - Cardiff Oncology reported positive initial data from its CRDF-004 trial, showing an objective response rate of 64% in patients receiving onvansertib in combination with standard care, compared to 33% in the control group [15][19] - Checkpoint Therapeutics received FDA approval for UNLOXCYT, marking a significant milestone for the company and providing a differentiated treatment option for patients with advanced cutaneous squamous cell carcinoma [5][20] Industry Trends - The global Cancer Immunotherapy Market is projected to grow at a CAGR of 12.84%, reaching $258.22 billion by 2031, indicating rapid growth and critical importance in oncology [7] - The American Cancer Society highlighted a concerning rise in early-onset colorectal cancer cases, exacerbated by disruptions in cancer care due to the COVID-19 pandemic [13] Collaborations and Partnerships - Personalis and Tempus AI expanded their commercial relationship to bring ultra-sensitive MRD testing to market, with Tempus serving as the exclusive commercial diagnostic partner for Personalis' NeXT Personal® Dx [4][10][16]